Also known as: Thymic Peptide Complex, Thymalin Khavinson Preparation
Half-life: Variable (peptide complex)
Last reviewed: · Published:
Thymalin is the original thymic peptide preparation from the Khavinson family, developed in the 1980s from bovine thymic tissue extracts. Unlike the later synthetic short peptides in the Khavinson family (Thymagen / Thymogen, Vilon, Crystagen), Thymalin is a complex of multiple thymic peptides rather than a single defined molecule. It is one of the most extensively used and longest-studied compounds in the Khavinson bioregulator catalog, with over 40 years of Russian clinical use across immune-deficient and elderly populations.
Russian clinical evidence base for Thymalin is substantial — including hundreds of observational and clinical studies in HIV/AIDS, viral hepatitis, recurrent infections, post-surgical immune recovery, oncology adjunct, and age-related immune decline. Reported outcomes have included improvements in T-cell numbers (particularly CD4+ subset), CD4/CD8 ratios, NK-cell function, and clinical infection rates. A long-term follow-up study by the Khavinson group reported reduced mortality over a 6-year observation period in elderly subjects receiving periodic Thymalin courses.
Thymalin is sold by research-chemical vendors outside Russia. Western clinical validation is essentially absent. The compound is a complex rather than a defined single molecule, which complicates regulatory characterization and limits its potential for Western clinical adoption. It remains the most widely used and most-studied Khavinson immunomodulator in Russian practice.
Thymalin was developed in the early 1980s by Vyacheslav Morozov and Vladimir Khavinson at the Institute of Experimental Medicine in St. Petersburg as a bovine thymic peptide complex. The compound entered Russian clinical use in the mid-1980s and has been continuously used since then across multiple medical specialties. The long-term Khavinson observational study of periodic Thymalin courses in elderly subjects (published 2003) is one of the most-cited pieces of evidence for the broader Khavinson bioregulator framework.
Forty years of Russian clinical use have established Thymalin as a well-tolerated immunomodulator, including in immunocompromised populations like HIV/AIDS patients. The principal theoretical concern, as with all immunomodulators, is the use in active autoimmune disease where the direction of immune shift could be unfavorable. The peptide-complex nature of Thymalin (rather than a single defined molecule) makes it slightly more variable batch-to-batch than synthetic short peptides.
Dose Range
5-30 mg
Frequency
Once daily IM or SubQ
Duration
5-10 day course, repeated 2-3 times per year
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
10 mg
Water Type
Sterile water for injection (clinical) or bacteriostatic water (research)
Mixing Volume
1-2 mL
Half-Life
Variable (peptide complex)
Molecular Weight
Complex mixture
Store reconstituted vial refrigerated at 2-8°C. Use within 7-14 days (as a peptide complex, less stable than synthetic short peptides). Intramuscular or subcutaneous administration is typical in Russian clinical use.
Disclosure: PinnyPeptide may earn a commission on purchases made through the links above, at no extra cost to you. We only list vendors we're willing to point our community at, but inclusion is not a clinical endorsement. Always verify each vendor's third-party testing and your local legal status before purchasing.
FDA Status
Not FDA approved.
Legal Status
Used in clinical practice in Russia and some former Soviet states. Research chemical elsewhere.
USA
Not approvedResearch-only
EU
Not approvedNot authorized as medicinal product
UK
Not approvedClassified as research chemical
Russia
Approved / used clinicallyUsed as immunomodulator in Russian medicine since 1980s
Australia
Not approvedTGA has not evaluated
Canada
Not approvedNot authorized for human use
Khavinson VK, Morozov VG
Neuroendocrinology Letters (2003)
Long-term observational study reporting reduced mortality in elderly subjects receiving periodic Thymalin and Epitalon courses over a 6-year period — one of the most-cited pieces of evidence for the Khavinson bioregulator framework.
No online link available — see journal archive.
Morozov VG, Khavinson VK
International Immunology (1997)
Comprehensive review by the discoverers of Thymalin covering the thymic peptide complex's immunological effects and clinical applications across multiple disease contexts.
View Study →Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS
Bulletin of Experimental Biology and Medicine (2015)
Foundational Khavinson-group review including extensive coverage of Thymalin's clinical use across the immune-aging spectrum.
View Study →Khavinson short peptide bioregulator targeting thymic function — Glu-Trp synthetic version.
Khavinson Lys-Glu dipeptide — immunomodulator with documented life-extension activity in mice.
Khavinson short peptide bioregulator targeting thymus / immune cells.
Thymic peptide with broad immunomodulatory activity, approved in over 35 countries.
Track Thymalin and more with PinnyPeptide.
Sign Up to Track ThymalinFree forever · defaults pre-filled from this article